|
|
Volumn 43, Issue 4, 2004, Pages 524-526
|
|
Treatment of myositis with etanercept (Enbrel®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1 [4]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZATHIOPRINE;
CORTICOSTEROID;
CYCLOPHOSPHAMIDE;
CYCLOSPORIN;
CYTOTOXIC AGENT;
ETANERCEPT;
IMMUNOGLOBULIN;
IMMUNOGLOBULIN G1;
IMMUNOMODULATING AGENT;
IMMUNOSUPPRESSIVE AGENT;
INFLIXIMAB;
LACTATE DEHYDROGENASE;
METHOTREXATE;
METHYLPREDNISOLONE;
PREDNISONE;
RECEPTOR SUBTYPE;
RECOMBINANT PROTEIN;
TUMOR NECROSIS FACTOR ALPHA RECEPTOR;
ACUPUNCTURE;
ADULT;
BINDING AFFINITY;
CASE REPORT;
CLINICAL FEATURE;
DRUG RECEPTOR BINDING;
ELECTROMYOGRAPHY;
FEMALE;
HUMAN;
IMMUNOHISTOCHEMISTRY;
KIDNEY DYSFUNCTION;
LABORATORY TEST;
LACTATE DEHYDROGENASE BLOOD LEVEL;
LETTER;
LIVER DYSFUNCTION;
MUSCLE BIOPSY;
MUSCLE STRENGTH;
MUSCLE WEAKNESS;
POLYMYOSITIS;
PRIORITY JOURNAL;
TREATMENT PLANNING;
|
|
EID: 1842844290
PISSN: 14620324
EISSN: None
Source Type: Journal
DOI: 10.1093/rheumatology/keh062 Document Type: Letter |
|
Times cited : (75)
|
|
References (4)
|
